Micah Young was named Chief Financial Officer of QuidelOrtho Corp, effective July 6, 2026. As of November 6, 2026, QuidelOrtho Corp has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 23, 2026 to November 3, 2026, naming 2 appointments (Form 8-K, June 23, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like QuidelOrtho Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
QuidelOrtho Corp reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-23 to 2026-11-03. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as QuidelOrtho Corp files it.
Also on the record for QuidelOrtho Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 7, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 5.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Newtyn Management, LLC | 9.7% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 2.6% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G, by Invesco Ltd. | 5.1% of the class | 5%+ stakes | Source |
| August 5, 2026 | Stake report, Schedule 13G/A, by Neuberger Berman Group LLC | 4.9% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G, by Neuberger Berman Group LLC | 5.2% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 11.5% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G, by Newtyn Management, LLC | 6.7% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 9.7% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by Invesco Ltd. | 4.6% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by Newtyn Management, LLC | 7.8% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.24% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs QuidelOrtho Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on QuidelOrtho Corp and the records around it.
QuidelOrtho Corp elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Newtyn Management, LLC also filed stake reports on 13 other companies: Par Technology Corporation (Aug 2026), Theravance Biopharma, Inc. (Aug 2026), ZOOZ Strategy Ltd. (Aug 2026)
- Rubric Capital Management LP also filed stake reports on 32 other companies: ARDELYX, INC. (Aug 2026), Enovis Corporation (Aug 2026), MeiraGTx Holdings plc (Aug 2026)
- Neuberger Berman Group LLC also filed stake reports on 37 other companies: Stock Yards Bancorp, Inc. (Nov 2026), TRANSCAT INC (Nov 2026), Hagerty Inc CLass A (Oct 2026)
Watch QuidelOrtho Corp
Get an email when QuidelOrtho Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on QuidelOrtho Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on QuidelOrtho Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on QuidelOrtho Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 23 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-03 | In | 2026-11-09 | 8-K, 2026-11-03 | ||
| 2026-06-23 | In | Chief Financial Officer | 2026-07-06 | 8-K, 2026-06-23 |
Who leads QuidelOrtho Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Micah Young, appointed, effective 2026-07-06 (filed 2026-06-23).
New leaders reset buying decisions — get the Full Report on QuidelOrtho Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at QuidelOrtho Corp, with the record behind each one.
Find candidates like Chief Financial Officer at QuidelOrtho CorpEvery change, in the filing's words
Appointed: Jonathan Siegrist, effective 2026-11-09
In connection with the Restructuring Plan, effective November 9, 2026 (the "Effective Date"), the QuidelOrtho Board of Directors (the "Board") has appointed Jonathan Siegrist, PhD to serve in the newly created role of Head of Point of Care Diagnostics and Bryan Hanson to serve in the newly created role of Head of Core Diagnostics.
- As reported in the Press Release, QuidelOrtho has initiated a cost transformation and enterprise restructuring program (the "Restructuring Plan") designed to further improve its cost structure and evolve its operating model around two focused businesses, Core Diagnostics and Point of Care Diagnostics.
- Prior to their appointment to such roles, Dr. Siegrist served as QuidelOrtho's Executive Vice President of Research & Development & Chief Technology Officer, and Mr. Hanson served as QuidelOrtho's Executive Vice President, Global Portfolio Management and Marketing.
- In connection with the appointment of Dr. Siegrist and Mr. Hanson to such new roles, QuidelOrtho entered into new employment offer letters with each of Dr. Siegrist and Mr. Hanson that provide for (i) an annual base salary of $650,000 and (ii) an annual target cash bonus opportunity of 100% of base salary.
- Each of Dr. Siegrist and Mr. Hanson will also receive a cash retention bonus in the amount of $650,000 that vests in full and is payable 12-months after the Effective Date.
Appointed: Micah Young, Chief Financial Officer, effective 2026-07-06
Announcement of New Chief Financial Officer The Board of Directors of QuidelOrtho Corporation (the "Company") has appointed Micah Young to serve as the Company's Chief Financial Officer and principal financial officer, effective as of July 6, 2026 (the "Effective Date").
- Mr. Busky has agreed to continue to serve in his current role through the Effective Date, and in connection therewith, is expected to enter into a transition and retirement agreement to provide for the smooth and orderly transition of his duties.
- Mr. Young (age 48) most recently served as Executive Vice President and Chief Financial Officer of Masimo Corporation (formerly, Nasdaq: MASI), a global medical technology company, from October 2017 until Masimo's acquisition by Danaher Corporation in June 2026.
- In this role, Mr. Young was responsible for finance and accounting functions, as well as investor relations, information technology and corporate development.
- From 2009 to 2017, Mr. Young served in various finance roles at NuVasive, Inc. (formerly, Nasdaq: NUVA), a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders, including most recently as Vice President, Finance.
- From 2002 to 2009, Mr. Young held various accounting and finance positions with Zimmer Holdings, Inc., a company focused on the design, development, manufacture and marketing of orthopedic reconstructive, spinal and trauma devices, dental implants and related surgical products.
- Prior to his time at Zimmer Holdings, Inc., Mr. Young was an auditor at Deloitte & Touche LLP from 2000 to 2002.
Tools for this story
Each opens in a new tab, filled in for QuidelOrtho Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.